论文部分内容阅读
目的:观察乌司他丁对重症急性胰腺炎(SAP)伴腹内高压患者腹内压及肠黏膜功能的影响。方法:选取2015年1月—2015年10月间收治的SAP伴腹内高压患者40例,将其分为乌司他丁组(UTI组)及对照组,每组20例;对照组患者均给予常规治疗,UTI组在对照组治疗的基础上再给予乌司他丁治疗;比较两组患者治疗后腹内压(OAP)、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和血浆二胺氧化酶(DAO)水平值的变化情况。结果:治疗后48 h UTI组患者腹内压明显低于对照组(P<0.05);治疗后24 h及治疗后48 h UTI组患者IL-6水平明显低于对照组(P<0.05);治疗后48 h UTI组患者DAO水平明显低于对照组(P<0.05)。结论:采用乌司他丁治疗重症急性胰腺炎(SAP)伴腹内高压患者,可明显降低腹内压,改善肠黏膜功能,疗效较为显著。
Objective: To observe the effects of ulinastatin on intra-abdominal pressure and intestinal mucosal function in patients with severe acute pancreatitis (SAP) complicated with intra-abdominal hypertension. Methods: Forty patients with SAP with intra-abdominal hypertension were selected from January 2015 to October 2015. They were divided into ulinastatin group (UTI group) and control group (20 cases in each group). Patients in control group The patients in the UTI group were treated with ulinastatin on the basis of the control group. The levels of intra-abdominal pressure (OAP), interleukin-6 (IL-6), interleukin-8 (IL-8) and plasma diamine oxidase (DAO) level changes. Results: The intra-abdominal pressure of UTI group was significantly lower than that of control group at 48 h after treatment (P <0.05). The levels of IL-6 in UTI group at 24 h and 48 h after treatment were significantly lower than those in control group (P <0.05). At 48 h after treatment, the DAO level in the UTI group was significantly lower than that in the control group (P <0.05). Conclusion: Ulinastatin treatment of patients with severe acute pancreatitis (SAP) with intra-abdominal hypertension can significantly reduce intra-abdominal pressure, improve intestinal mucosal function, the effect is more significant.